PMC:7228307 / 43198-43358 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"815","span":{"begin":125,"end":129},"obj":"Gene"},{"id":"832","span":{"begin":53,"end":58},"obj":"Mutation"},{"id":"833","span":{"begin":60,"end":65},"obj":"Mutation"},{"id":"834","span":{"begin":67,"end":72},"obj":"Mutation"}],"attributes":[{"id":"A815","pred":"tao:has_database_id","subj":"815","obj":"Gene:2213"},{"id":"A832","pred":"tao:has_standard_notation","subj":"832","obj":"p.L234F"},{"id":"A833","pred":"tao:has_standard_notation","subj":"833","obj":"p.L235E"},{"id":"A834","pred":"tao:has_standard_notation","subj":"834","obj":"p.P331S"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Anifrolumab Interferon alpha/beta receptor 1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding Immunology Phase III"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T769","span":{"begin":125,"end":127},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"Anifrolumab Interferon alpha/beta receptor 1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding Immunology Phase III"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T222","span":{"begin":24,"end":29},"obj":"Chemical"},{"id":"T223","span":{"begin":30,"end":34},"obj":"Chemical"}],"attributes":[{"id":"A222","pred":"chebi_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"},{"id":"A223","pred":"chebi_id","subj":"T223","obj":"http://purl.obolibrary.org/obo/CHEBI_10545"}],"text":"Anifrolumab Interferon alpha/beta receptor 1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding Immunology Phase III"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"815","span":{"begin":125,"end":129},"obj":"Gene"},{"id":"832","span":{"begin":53,"end":58},"obj":"Mutation"},{"id":"833","span":{"begin":60,"end":65},"obj":"Mutation"},{"id":"834","span":{"begin":67,"end":72},"obj":"Mutation"}],"attributes":[{"id":"A815","pred":"pubann:denotes","subj":"815","obj":"Gene:2213"},{"id":"A832","pred":"pubann:has_HGVS_notation","subj":"832","obj":"p.L234F"},{"id":"A833","pred":"pubann:has_HGVS_notation","subj":"833","obj":"p.L235E"},{"id":"A834","pred":"pubann:has_HGVS_notation","subj":"834","obj":"p.P331S"}],"text":"Anifrolumab Interferon alpha/beta receptor 1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding Immunology Phase III"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T245","span":{"begin":0,"end":160},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Anifrolumab Interferon alpha/beta receptor 1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding Immunology Phase III"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T429","span":{"begin":13,"end":45},"obj":"Protein"}],"attributes":[{"id":"A429","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/Q95206"},{"id":"A430","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/Q8WTZ2"},{"id":"A431","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/Q80UJ3"},{"id":"A432","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/Q7M4L2"},{"id":"A433","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/Q764M8"},{"id":"A434","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/Q6PKD7"},{"id":"A435","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/Q53H11"},{"id":"A436","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/Q53GW9"},{"id":"A437","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/Q28589"},{"id":"A438","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/Q04790"},{"id":"A439","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/P33896"},{"id":"A440","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/P17181"},{"id":"A441","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/D3DSF0"},{"id":"A442","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/B4DNT3"},{"id":"A443","pred":"uniprot_id","subj":"T429","obj":"https://www.uniprot.org/uniprot/B2R6L9"}],"text":"Anifrolumab Interferon alpha/beta receptor 1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding Immunology Phase III"}

{"project":"LitCovid-sentences","denotations":[{"id":"T245","span":{"begin":0,"end":160},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Anifrolumab Interferon alpha/beta receptor 1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding Immunology Phase III"}